Polarean Imaging PLC Scientific presentations on hyperpolarized Xenon

TIDMPOLX

Polarean Imaging PLC

30 July 2020

Polarean Imaging plc

("Polarean" or the "Company")

Scientific presentations on hyperpolarized (129) Xenon at upcoming medical meetings

   -      Polarean's investigational drug/device lung diagnostic to be prominently featured 

- Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical -- imaging technology company, with a proprietary drug -- device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 ("(129) Xe") will be made by leading academic researchers at the upcoming American Thoracic Society ("ATS") virtual conference and the International Society for Magnetic Resonance in Medicine ("ISMRM") virtual conference. The ATS and ISMRM conferences are taking place between 5-10 August 2020 and 8-14 August 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized (129) Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, 5 August 2020:

 
    ATS 2020 Abstract Title and Lead Author       Poster Number   Session Number 
 Coleman EM et al. Hyperpolarized (129)                523             D28 
  Xe Identifies Ventilation Responders 
  to Glycopyrrolate/Formoterol Furmarate 
  in Chronic Obstructive Lung Disease 
                                                 --------------  --------------- 
 Bier EA et al. Monitoring Response                    593             B56 
  to Inhaled Prostacyclin Therapy with 
  (129) Xenon MR Imaging and Spectroscopy 
  in Patients with Pulmonary Hypertension 
                                                 --------------  --------------- 
 Neidbalski PJ et al. Hyperpolarized                   622             A68 
  (129) Xe MRI of Regional Capillary-Level 
  Cardio-Pulmonary Dynamics Predict Outcomes 
  in IPF Patients 
                                                 --------------  --------------- 
 Bier EA et al. Noninvasive Diagnosis                  633             B58 
  of Pulmonary Hypertension with Hyperpolarized 
  (129) Xe Magnetic Resonance Imaging 
  and Spectroscopy 
                                                 --------------  --------------- 
 Mummy D et al. Hyperpolarized Xe-129                  705             D110 
  MRI Measures of Gas Exchange in Non-specific 
  Interstitial Pneumonia 
                                                 --------------  --------------- 
 Wang Z et al. Spatial Correlation of                  706             D110 
  (129) Xenon Gas Exchange MRI with (99m) 
  Tc Perfusion Scintigraphy 
                                                 --------------  --------------- 
 Wang Z et al. Using (129) Xenon MR                    707             D110 
  Gas Exchange MRI to Measure the Membrane 
  and Capillary Components of DL(CO) 
  and K(CO) 
                                                 --------------  --------------- 
 Mummy D et al. Hyperpolarized (129)                   713             D110 
  Xe MRI is sensitive to therapy response 
  in idiopathic pulmonary fibrosis 
                                                 --------------  --------------- 
 Shim YM et al. Positive Results from                 1027             B39 
  Two Randomized Phase III Trials Assessing 
  Hyperpolarized 129Xenon 
  Gas MRI as a Measure of Regional Lung 
  Function as Compared to Imaging with 
  133Xenon Scintigraphy 
                                                 --------------  --------------- 
 

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days and times:

 
       ISMRM 2020 Abstract Title and Lead         Program    Session Name       Date 
                     Author                        Number 
 Bier EA et al. Noninvasive Diagnosis              2283     Hyperpolarized   8-14 August 
  of Pulmonary Hypertension with Hyperpolarized                Gas/Lung 
  (129) Xe Magnetic                                               MRI 
  Resonance Imaging and Spectroscopy 
                                                 --------  ---------------  ------------ 
 Mummy D et al. Hyperpolarized (129)               2291        Thoracic      8-14 August 
  Xe MRI Measures of Gas Exchange in                           & Breast 
  Non-specific Interstitial Pneumonia                             MRI 
                                                 --------  ---------------  ------------ 
 Niedbalski PJ et al. Imaging Regional             0432        Thoracic       11 August 
  Capillary Cardio-Pulmonary Blood Flow                           MRI 
  Dynamics using Hyperpolarized (129) 
  Xe MRI and Keyhole Reconstruction 
                                                 --------  ---------------  ------------ 
 Rankine L et al. Quantitative dose-dependent      0431        Thoracic       11 August 
  changes in regional lung function                               MRI 
  after radiation therapy detected using 
  xenon-129 gas exchange MRI 
                                                 --------  ---------------  ------------ 
 Lu J et al. Bias field correction                 0451       Pulmonary       11 August 
  in hyperpolarized (129) Xe ventilation                         Power 
  imaging 
                                                 --------  ---------------  ------------ 
 Wang Z et al. A model for interpreting            0443       Pulmonary       11 August 
  hyperpolarized (129) Xe exchange MRI                           Power 
                                                 --------  ---------------  ------------ 
 

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM. Session W-02 takes place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: "We are pleased to see (129) Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized (129) Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean's products to conduct research, highlighting the growing academic acceptance of the Company's technology. We hope that the inclusion of so many sessions on (129) Xenon will continue to showcase Polarean's important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system."

Contacts:

 
 Polarean Imaging plc                         www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive                                   Via Walbrook PR 
  Officer 
  Jonathan Allis, Chairman 
 
 Walbrook PR                     Tel: [phone] or [e-mail] 
 Paul McManus / Anna Dunphy                   Mob: [phone] 
                                                                             741 001 
 
 

About Polarean ( www.polarean.com )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas ((129) Xe) as an imaging agent to visualize ventilation.(129) Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging (129) Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAEAKXNALEEEFA

(END) Dow Jones Newswires

July 30, 2020 02:00 ET (06:00 GMT)